Merck & Co., Inc.

“Merck is a high-quality pharmaceutical business in structural transition: Keytruda generates exceptional cash flows today but faces simultaneous IRA price negotiation and biosimilar competition at the 2028 LOE cliff, creating a binary outcome that hinges entirely on whether the pipeline — anchored by MK-7240, subcutaneous Keytruda, and Daiichi Sankyo ADC collaborations — can replace $15-20B of high-margin revenue. Net debt has deteriorated to $34.8B, FCF declined to $12.4B in 2025, and the payout ratio exceeds 93% — leaving no financial flexibility if the pipeline disappoints. At 12.4x forward earnings, the cliff is partially priced in but not fully, and conviction in a positive pipeline outcome is insufficiently high to buy at current levels. Track for pipeline catalysts or a more attractive entry.”